

# Sooryanarayana Varambally

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3485645/sooryanarayana-varambally-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

140 papers	27,882 citations	61 h-index	156 g-index
156 ext. papers	32,319 ext. citations	11.8 avg, IF	6.41 L-index

#	Paper	IF	Citations
140	UALCAN: An update to the integrated cancer data analysis platform.. <i>Neoplasia</i> , <b>2022</b> , 25, 18-27	6.4	44
139	Meta-analysis of the robustness of COVID-19 diagnostic kit performance during the early pandemic.. <i>BMJ Open</i> , <b>2022</b> , 12, e053912	3	
138	Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways.. <i>Nature Communications</i> , <b>2022</b> , 13, 2669	17.4	3
137	Distinct Gene Expression Profiles of Matched Primary and Metastatic Triple-Negative Breast Cancers. <i>Cancers</i> , <b>2022</b> , 14, 2447	6.6	
136	Global molecular alterations involving recurrence or progression of pediatric brain tumors. <i>Neoplasia</i> , <b>2021</b> , 24, 22-33	6.4	1
135	MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia By Enhancing Common $\gamma$ Chain Cytokine Receptor Endocytosis. <i>Blood</i> , <b>2021</b> , 138, 59-59	2.2	
134	The TGF- $\beta$ /HDAC7 axis suppresses TCA cycle metabolism in renal cancer. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	1
133	Expression of MHC class I polypeptide-related sequence A (MICA) in colorectal cancer. <i>Frontiers in Bioscience</i> , <b>2021</b> , 26, 765-776		2
132	NAB2-STAT6 Gene Fusions to Evaluate Primary/Metastasis of Hemangiopericytoma/Solitary Fibrous Tumors. <i>American Journal of Clinical Pathology</i> , <b>2021</b> , 156, 906-912	1.9	2
131	Subcellular localization of EZH2 phosphorylated at T367 stratifies metaplastic breast carcinoma subtypes. <i>Breast Cancer</i> , <b>2021</b> , 28, 496-505	3.4	3
130	Meta-Analysis of Robustness of COVID-19 Diagnostic Kits During Early Pandemic <b>2021</b> ,		1
129	Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancers. <i>Oncogene</i> , <b>2021</b> , 40, 2081-2095	9.2	8
128	Comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian Women. <i>Translational Oncology</i> , <b>2021</b> , 14, 101086	4.9	3
127	Collagen modifying enzyme P4HA1 is overexpressed and plays a role in lung adenocarcinoma. <i>Translational Oncology</i> , <b>2021</b> , 14, 101128	4.9	2
126	Comparative transcriptome analyses reveal genes associated with SARS-CoV-2 infection of human lung epithelial cells. <i>Scientific Reports</i> , <b>2021</b> , 11, 16212	4.9	6
125	PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. <i>Translational Oncology</i> , <b>2020</b> , 13, 100776	4.9	7
124	Fermentable fiber-induced hepatocellular carcinoma in mice recapitulates gene signatures found in human liver cancer. <i>PLoS ONE</i> , <b>2020</b> , 15, e0234726	3.7	3

123	Targeting P4HA1 with a Small Molecule Inhibitor in a Colorectal Cancer PDX Model. <i>Translational Oncology</i> , <b>2020</b> , 13, 100754	4.9	13
122	Fermentable fibers induce rapid macro- and micronutrient depletion in Toll-like receptor 5-deficient mice. <i>American Journal of Physiology - Renal Physiology</i> , <b>2020</b> , 318, G955-G965	5.1	1
121	PAICS, a Purine Nucleotide Metabolic Enzyme, is Involved in Tumor Growth and the Metastasis of Colorectal Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	15
120	MicroRNA-mediated inflammation and coagulation effects in rats exposed to an inhaled analog of sulfur mustard. <i>Annals of the New York Academy of Sciences</i> , <b>2020</b> , 1479, 148-158	6.5	7
119	Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. <i>Oncogene</i> , <b>2020</b> , 39, 4077-4091	9.2	8
118	14-3-3 proteins protect AMPK-phosphorylated ten-eleven translocation-2 (TET2) from PP2A-mediated dephosphorylation. <i>Journal of Biological Chemistry</i> , <b>2020</b> , 295, 1754-1766	5.4	10
117	Dysregulation of de novo nucleotide biosynthetic pathway enzymes in cancer and targeting opportunities. <i>Cancer Letters</i> , <b>2020</b> , 470, 134-140	9.9	23
116	TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status. <i>Molecular Oncology</i> , <b>2020</b> , 14, 3007-3029	7.9	13
115	PGC1 $\beta$ suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression. <i>Matrix Biology</i> , <b>2020</b> , 89, 43-58	11.4	10
114	PRDM16 suppresses HIF-targeted gene expression in kidney cancer. <i>Journal of Experimental Medicine</i> , <b>2020</b> , 217,	16.6	11
113	EZH2-Targeted Therapies in Cancer: Hype or a Reality. <i>Cancer Research</i> , <b>2020</b> , 80, 5449-5458	10.1	40
112	Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer. <i>Neoplasia</i> , <b>2019</b> , 21, 989-1002	6.4	9
111	Inhibition of Hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancer. <i>Oncotmunology</i> , <b>2019</b> , 8, 1548241	7.2	39
110	The combined survival effect of codon 72 polymorphisms and p53 somatic mutations in breast cancer depends on race and molecular subtype. <i>PLoS ONE</i> , <b>2019</b> , 14, e0211734	3.7	6
109	Ferritin Light Chain Confers Protection Against Sepsis-Induced Inflammation and Organ Injury. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 131	8.4	33
108	Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 84-96	6.6	26
107	Genome-wide DNA methylation encodes cardiac transcriptional reprogramming in human ischemic heart failure. <i>Laboratory Investigation</i> , <b>2019</b> , 99, 371-386	5.9	38
106	Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer. <i>Translational Oncology</i> , <b>2019</b> , 12, 1416-1424	4.9	7

105	Characterization of glycine-N-acyltransferase like 1 (GLYATL1) in prostate cancer. <i>Prostate</i> , <b>2019</b> , 79, 1629-1639	4.2	4
104	MTHFD1L, A Folate Cycle Enzyme, Is Involved in Progression of Colorectal Cancer. <i>Translational Oncology</i> , <b>2019</b> , 12, 1461-1467	4.9	19
103	Pan-cancer molecular subtypes revealed by mass-spectrometry-based proteomic characterization of more than 500 human cancers. <i>Nature Communications</i> , <b>2019</b> , 10, 5679	17.4	150
102	Large-scale profiling of serum metabolites in African American and European American patients with bladder cancer reveals metabolic pathways associated with patient survival. <i>Cancer</i> , <b>2019</b> , 125, 921-932	6.4	22
101	Molecular Correlates of Metastasis by Systematic Pan-Cancer Analysis Across The Cancer Genome Atlas. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 476-487	6.6	15
100	Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 591-602	6.1	50
99	Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets. <i>European Urology Focus</i> , <b>2018</b> , 4, 733-736	5.1	16
98	miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. <i>Molecular Cancer Research</i> , <b>2018</b> , 16, 1125-1137	6.6	31
97	Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. <i>Matrix Biology</i> , <b>2018</b> , 65, 104-118	11.4	125
96	Wnt receptor Frizzled 8 is a target of ERG in prostate cancer. <i>Prostate</i> , <b>2018</b> , 78, 1311-1320	4.2	13
95	A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression. <i>Neoplasia</i> , <b>2018</b> , 20, 894-904	6.4	25
94	Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 179-184	1.9	5
93	Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cells. <i>Scientific Reports</i> , <b>2017</b> , 7, 43984	4.9	12
92	Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. <i>Cancer Cell</i> , <b>2017</b> , 31, 532-548.e7	24.3	57
91	Prostate Cancer: An Update on Molecular Pathology with Clinical Implications. <i>European Urology Supplements</i> , <b>2017</b> , 16, 253-271	0.9	1
90	UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. <i>Neoplasia</i> , <b>2017</b> , 19, 649-658	6.4	2229
89	Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer. <i>Prostate</i> , <b>2017</b> , 77, 10-21	4.2	27
88	Prostate Cancer Imaging and Biomarkers Guiding Safe Selection of Active Surveillance. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 256	5.3	15

87	MicroRNA-101 regulated transcriptional modulator SUB1 plays a role in prostate cancer. <i>Oncogene</i> , <b>2016</b> , 35, 6330-6340	9.2	43
86	Genomic and Epigenomic Alterations in Cancer. <i>American Journal of Pathology</i> , <b>2016</b> , 186, 1724-35	5.8	84
85	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. <i>Nature Medicine</i> , <b>2016</b> , 22, 298-305	50.5	775
84	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. <i>Nature Immunology</i> , <b>2016</b> , 17, 95-103	19.1	234
83	EZH2 Upregulation Is Associated with Unfavorable Prognosis in Diffuse Large B-Cell Lymphoma through Potential RUNX3 Downregulation. <i>Blood</i> , <b>2016</b> , 128, 5301-5301	2.2	
82	Increased Expression of EZH2 Is Associated with Inferior Survival in Primary Central Nervous System Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 4216-4216	2.2	
81	Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma. <i>Cell Cycle</i> , <b>2015</b> , 14, 2798-809	4.7	13
80	Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 23445-61	3.3	49
79	The kinase activity of the Ser/Thr kinase BUB1 promotes TGF- $\beta$ signaling. <i>Science Signaling</i> , <b>2015</b> , 8, ra1	8.8	50
78	TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. <i>Nature Communications</i> , <b>2014</b> , 5, 4527	17.4	81
77	The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. <i>Oncotarget</i> , <b>2014</b> , 5, 6654-69	3.3	70
76	Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. <i>Molecular Cell</i> , <b>2013</b> , 49, 80-93	17.6	110
75	Targeting the link between late pregnancy and breast cancer. <i>ELife</i> , <b>2013</b> , 2, e01926	8.9	4
74	Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. <i>Blood</i> , <b>2012</b> , 119, 1274-82	2.2	54
73	Role of transcriptional corepressor CtBP1 in prostate cancer progression. <i>Neoplasia</i> , <b>2012</b> , 14, 905-14	6.4	49
72	Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models. <i>Prostate</i> , <b>2012</b> , 72, 1542-9	4.2	12
71	The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 43862-75	5.4	14
70	Therapeutic targeting of SPINK1-positive prostate cancer. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 72ra17	17.5	120

69	Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. <i>Blood</i> , <b>2011</b> , 117, 6172-83	2.2	116
68	The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. <i>Oncogene</i> , <b>2011</b> , 30, 4339-49	9.2	86
67	Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. <i>Cancer Cell</i> , <b>2011</b> , 19, 664-78	24.3	342
66	Coordinated regulation of polycomb group complexes through microRNAs in cancer. <i>Cancer Cell</i> , <b>2011</b> , 20, 187-99	24.3	176
65	TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. <i>Cancer Research</i> , <b>2011</b> , 71, 5387-92	10.1	40
64	Characterization of KRAS rearrangements in metastatic prostate cancer. <i>Cancer Discovery</i> , <b>2011</b> , 1, 35-43	24.4	83
63	Inhibition of Histone Methylation Arrests Ongoing Graft-Versus-Host Diseases in Mice by Selectively Inducing Apoptosis of Alloreactive Effector T Cells. <i>Blood</i> , <b>2011</b> , 118, 820-820	2.2	
62	The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. <i>Oncogene</i> , <b>2010</b> , 29, 5370-80	9.2	68
61	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. <i>Nature Medicine</i> , <b>2010</b> , 16, 793-8	50.5	382
60	Antibody-based detection of ERG rearrangement-positive prostate cancer. <i>Neoplasia</i> , <b>2010</b> , 12, 590-8	6.4	281
59	Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. <i>Eur Urol</i> 2010;58:12-8. <i>European Urology</i> , <b>2010</b> , 58, e29-30; author reply e31-2	10.2	16
58	An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. <i>Cancer Cell</i> , <b>2010</b> , 17, 443-54	24.3	640
57	Induced chromosomal proximity and gene fusions in prostate cancer. <i>Science</i> , <b>2009</b> , 326, 1230	33.3	299
56	AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 10284-9	11.5	111
55	Tomlins et al. reply. <i>Nature</i> , <b>2009</b> , 457, E2-E3	50.4	5
54	Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. <i>Nature</i> , <b>2009</b> , 457, 910-4	50.4	1636
53	An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. <i>Nature Biotechnology</i> , <b>2009</b> , 27, 1005-11	44.5	63
52	RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. <i>Neoplasia</i> , <b>2009</b> , 11, 956-63	6.4	58

51	Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. <i>PLoS ONE</i> , <b>2009</b> , 4, e7075	3.7	39
50	Repression of E-cadherin by the polycomb group protein EZH2 in cancer. <i>Oncogene</i> , <b>2008</b> , 27, 7274-84	9.2	456
49	The role of SPINK1 in ETS rearrangement-negative prostate cancers. <i>Cancer Cell</i> , <b>2008</b> , 13, 519-28	24.3	254
48	Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. <i>American Journal of Pathology</i> , <b>2008</b> , 172, 893-904	5.8	56
47	Role of the TMPRSS2-ERG gene fusion in prostate cancer. <i>Neoplasia</i> , <b>2008</b> , 10, 177-88	6.4	522
46	Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. <i>Neoplasia</i> , <b>2008</b> , 10, 1285-94	6.4	74
45	Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. <i>Science</i> , <b>2008</b> , 322, 1695-9	33.3	888
44	A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 7629-37	10.1	127
43	Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 73-80	10.1	212
42	Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. <i>Neoplasia</i> , <b>2007</b> , 9, 166-80	6.4	1537
41	Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. <i>Neoplasia</i> , <b>2007</b> , 9, 443-54	6.4	118
40	Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. <i>Oncogene</i> , <b>2007</b> , 26, 3431-9	9.2	62
39	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. <i>Nature</i> , <b>2007</b> , 448, 595-9	50.4	654
38	Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. <i>Cancer Cell</i> , <b>2007</b> , 12, 419-31	24.3	185
37	A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. <i>Cancer Research</i> , <b>2007</b> , 67, 10657-63	10.1	270
36	Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 19488-93	11.5	152
35	Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 2512-8	12.9	47
34	Autoantibody profiles reveal ubiquitin 1 as a humoral immune response target in lung adenocarcinoma. <i>Cancer Research</i> , <b>2007</b> , 67, 3461-7	10.1	76



33	Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. <i>International Journal of Cancer</i> , <b>2006</b> , 118, 1041-50	7.5	33
32	Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2'5'Toligoadenylate synthetase from prostate cancer cells. <i>Nucleic Acids Research</i> , <b>2006</b> , 34, 6684-95	20.1	41
31	Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. <i>Journal of Experimental Medicine</i> , <b>2006</b> , 203, 203-13	16.6	173
30	A systems approach to model metastatic progression. <i>Cancer Research</i> , <b>2006</b> , 66, 5537-9	10.1	8
29	Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation. <i>Cancer Research</i> , <b>2006</b> , 66, 11554-9	10.1	24
28	Defining aggressive prostate cancer using a 12-gene model. <i>Neoplasia</i> , <b>2006</b> , 8, 59-68	6.4	73
27	ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. <i>Neoplasia</i> , <b>2006</b> , 8, 319-29	6.4	73
26	Differential proteomic alterations between localised and metastatic prostate cancer. <i>British Journal of Cancer</i> , <b>2006</b> , 95, 425-30	8.7	23
25	The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. <i>Neoplasia</i> , <b>2005</b> , 7, 1011-9	9.4	79
24	Autoantibody signatures in prostate cancer. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1224-35	59.2	521
23	Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. <i>Science</i> , <b>2005</b> , 310, 644-8	33.3	3022
22	Probabilistic model of the human protein-protein interaction network. <i>Nature Biotechnology</i> , <b>2005</b> , 23, 951-9	44.5	338
21	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. <i>Cancer Cell</i> , <b>2005</b> , 8, 393-406	24.3	625
20	Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2005</b> , 14, 1418-23	4	45
19	Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. <i>Cancer Research</i> , <b>2005</b> , 65, 11259-64	10.1	221
18	The unfolded protein response modulates toxicity of the expanded glutamine androgen receptor. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 21264-71	5.4	46
17	Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). <i>Cancer Research</i> , <b>2005</b> , 65, 3328-35	10.1	313
16	The role of metastasis-associated protein 1 in prostate cancer progression. <i>Cancer Research</i> , <b>2004</b> , 64, 825-9	10.1	116



15	Natural antibodies sustain differentiation and maturation of human dendritic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 14210-5	11.5	95
14	Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. <i>International Immunology</i> , <b>2004</b> , 16, 517-24	4.9	31
13	Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. <i>Cancer Research</i> , <b>2004</b> , 64, 3814-22	10.1	136
12	JAGGED1 expression is associated with prostate cancer metastasis and recurrence. <i>Cancer Research</i> , <b>2004</b> , 64, 6854-7	10.1	280
11	Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. <i>Cancer Research</i> , <b>2004</b> , 64, 9209-16	10.1	712
10	C5a-induced gene expression in human umbilical vein endothelial cells. <i>American Journal of Pathology</i> , <b>2004</b> , 164, 849-59	5.8	134
9	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 11606-11	11.5	1295
8	The polycomb group protein EZH2 is involved in progression of prostate cancer. <i>Nature</i> , <b>2002</b> , 419, 624-8	50.4	2085
7	Molecular cross-talk between the TRAIL and interferon signaling pathways. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 575-85	5.4	75
6	alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 287, 1662-70	27.4	489
5	alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 841-8	5.8	105
4	Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 1743-8	5.8	124
3	Delineation of prognostic biomarkers in prostate cancer. <i>Nature</i> , <b>2001</b> , 412, 822-6	50.4	1402
2	Comparative transcriptome analyses reveal genes associated with SARS-CoV-2 infection of human lung epithelial cells		2
1	ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibition		1